Suppr超能文献

瑞士出现产碳青霉烯酶高毒力肺炎克雷伯菌。

Emergence of Carbapenemase-Producing Hypervirulent Klebsiella pneumoniae in Switzerland.

机构信息

Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland.

Swiss National Reference Center for Emerging Antibiotic Resistance (NARA), University of Fribourg, Fribourg, Switzerland.

出版信息

Antimicrob Agents Chemother. 2023 Mar 16;67(3):e0142422. doi: 10.1128/aac.01424-22. Epub 2023 Feb 28.

Abstract

Increasing occurrence of multidrug-resistant (MDR) and hypervirulent (hv) Klebsiella pneumoniae (MDR-hvKp) convergent clones is being observed. Those strains have the potential of causing difficult-to-treat infections in healthy adults with an increased capacity for mortality. It is therefore crucial to track their dissemination to prevent their further spread. The aim of our study was to investigate the occurrence of carbapenemase-producing hvKp isolates in Switzerland and to determine their genetic profile. A total of 279 MDR carbapenemase-producing K. pneumoniae from patients hospitalized all over Switzerland was investigated, and a rate of 9.0% K. pneumoniae presenting a virulence genotype was identified. Those isolates produced either KPC, NDM, or OXA-48 and had been either recovered from rectal swabs, urine, and blood. A series of previously reported K. pneumoniae clones such as ST23-K1, ST395-K2, and ST147-K20 or ST147-K64 were identified. All the isolates defined as MDR-hvKp (4.7%) possessed the aerobactin and the yersiniabactin clusters. The ST23-K1s were the only isolates presenting the colibactin cluster and achieved higher virulence scores. This study highlights the occurrence and circulation of worrisome MDR-hvKp and MDR nonhypervirulent K. pneumoniae (MDR-nhv-Kp) isolates in Switzerland. Our findings raise an alert regarding the need for active surveillance networks to track and monitor the spread of such successful hybrid clones representing a public health threat worldwide.

摘要

越来越多的多药耐药(MDR)和高毒力(hv)肺炎克雷伯菌(MDR-hvKp)汇聚克隆正在出现。这些菌株有可能导致健康成年人发生难以治疗的感染,并增加死亡率。因此,追踪它们的传播以防止其进一步扩散至关重要。我们的研究目的是调查瑞士产碳青霉烯酶 MDR-hvKp 分离株的发生情况,并确定其遗传特征。对来自瑞士各地住院患者的 279 株 MDR 产碳青霉烯酶肺炎克雷伯菌进行了研究,发现有 9.0%的肺炎克雷伯菌具有毒力基因型。这些分离株产生 KPC、NDM 或 OXA-48,并且从直肠拭子、尿液和血液中回收。鉴定出了一系列先前报道的肺炎克雷伯菌克隆,如 ST23-K1、ST395-K2 和 ST147-K20 或 ST147-K64。所有被定义为 MDR-hvKp(4.7%)的分离株均具有aerobactin 和 yersiniabactin 簇。ST23-K1 是唯一携带 colibactin 簇的分离株,且具有更高的毒力评分。本研究强调了令人担忧的 MDR-hvKp 和 MDR 非高毒力肺炎克雷伯菌(MDR-nhv-Kp)分离株在瑞士的发生和传播。我们的研究结果表明,需要建立主动监测网络,以追踪和监测这些成功的混合克隆的传播,这些克隆代表了全球公共卫生威胁。

相似文献

1
Emergence of Carbapenemase-Producing Hypervirulent Klebsiella pneumoniae in Switzerland.瑞士出现产碳青霉烯酶高毒力肺炎克雷伯菌。
Antimicrob Agents Chemother. 2023 Mar 16;67(3):e0142422. doi: 10.1128/aac.01424-22. Epub 2023 Feb 28.

引用本文的文献

3
Multidrug-resistant hypervirulent : an evolving superbug.多重耐药性高毒力:一种不断演变的超级细菌
Future Microbiol. 2025 Apr;20(6):499-511. doi: 10.1080/17460913.2025.2482478. Epub 2025 Mar 26.
5
Emergence of -bearing MDR-hypervirulent ST307.携带耐药-高毒力ST307菌株的出现。
Microbiol Spectr. 2025 Feb 4;13(2):e0191024. doi: 10.1128/spectrum.01910-24. Epub 2024 Dec 13.

本文引用的文献

1
Molecular analysis of OXA-48-producing Escherichia coli in Switzerland from 2019 to 2020.2019 年至 2020 年瑞士产 OXA-48 型大肠埃希菌的分子分析。
Eur J Clin Microbiol Infect Dis. 2022 Nov;41(11):1355-1360. doi: 10.1007/s10096-022-04493-6. Epub 2022 Sep 14.
6
Hypervirulent Klebsiella pneumoniae ST23 producing OXA-48 in Switzerland.瑞士产OXA-48的高毒力肺炎克雷伯菌ST23
Int J Antimicrob Agents. 2021 Dec;58(6):106457. doi: 10.1016/j.ijantimicag.2021.106457. Epub 2021 Oct 24.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验